Travere Therapeutics (NASDAQ:TVTX) Stock Price Target Lowered at Leerink Partners

Travere Therapeutics (NASDAQ:TVTX) had its target price dropped by equities research analysts at Leerink Partners from $78.00 to $67.00 in a research report issued to clients and investors on Thursday, Benzinga reports. The firm presently has an “outperform” rating on the stock. Leerink Partners‘s target price indicates a potential upside of 37.10% from the stock’s current price.

Other equities analysts have also issued research reports about the stock. Zacks Research lowered shares of Travere Therapeutics from a “hold” rating to a “strong sell” rating in a report on Tuesday, October 20th. TD Cowen lifted their target price on shares of Travere Therapeutics from $60.00 to $75.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. Citigroup boosted their price target on shares of Travere Therapeutics from $70.00 to $85.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. Canaccord Genuity Group upped their price target on shares of Travere Therapeutics from $70.00 to $72.00 and gave the company a “buy” rating in a research report on Wednesday. Finally, Wedbush reaffirmed an “outperform” rating and set a $76.00 price objective on shares of Travere Therapeutics in a research note on Tuesday, September 22nd. Eleven investment analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $68.45.

Travere Therapeutics Price Performance

NASDAQ TVTX traded down $3.55 on Thursday, reaching $48.87. 2,180,102 shares of the company’s stock traded hands, compared to its average volume of 2,047,421. Travere Therapeutics has a 12 month low of $22.59 and a 12 month high of $68.73. The company has a debt-to-equity ratio of 26.72, a current ratio of 3.00 and a quick ratio of 3.99. The stock has a 50-day simple moving average of $58.12 and a 200 day simple moving average of $46.79. The stock has a market cap of $4.69 billion, a PE ratio of -37.88 and a beta of 1.11.

Travere Therapeutics (NASDAQ:TVTX) last posted its quarterly earnings results on Monday, November 2nd. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.49). The business had revenue of $224.56 million for the quarter, compared to analysts’ expectations of $195.29 million. Travere Therapeutics had a negative return on equity of 185.69% and a negative net margin of 18.66%. The company’s revenue was up 36.2% compared to the same quarter last year. During the same period last year, the business posted $0.28 earnings per share. As a group, research analysts predict that Travere Therapeutics will post -0.92 earnings per share for the current year.

Insider Buying and Selling

In related news, EVP Peter Heerma sold 172,717 shares of Travere Therapeutics stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $63.43, for a total value of $10,955,439.31. Following the transaction, the executive vice president directly owned 117,066 shares of the company’s stock, valued at $7,425,496.38. The trade was a 59.60% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Christopher Cline sold 50,508 shares of the company’s stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $62.34, for a total transaction of $3,148,668.72. Following the sale, the chief financial officer owned 87,508 shares of the company’s stock, valued at $5,455,248.72. This represents a 36.60% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 1,294,029 shares of company stock valued at $79,454,261 over the last quarter. Company insiders own 4.44% of the company’s stock.

Institutional Investors Weigh In On Travere Therapeutics

A number of large investors have recently added to or reduced their stakes in TVTX. GAMMA Investing LLC raised its stake in shares of Travere Therapeutics by 53.4% during the second quarter. GAMMA Investing LLC now owns 606 shares of the company’s stock valued at $34,000 after acquiring an additional 211 shares during the last quarter. Allworth Financial LP purchased a new stake in shares of Travere Therapeutics during the second quarter worth about $47,000. Fifth Third Bancorp purchased a new stake in shares of Travere Therapeutics during the first quarter worth about $35,000. Integrated Wealth Concepts LLC purchased a new stake in shares of Travere Therapeutics during the second quarter worth about $70,000. Finally, Rockefeller Capital Management L.P. grew its stake in shares of Travere Therapeutics by 1,604.5% in the fourth quarter. Rockefeller Capital Management L.P. now owns 2,642 shares of the company’s stock worth $101,000 after purchasing an additional 2,487 shares during the last quarter.

Key Stories Impacting Travere Therapeutics

Here are the key news stories impacting Travere Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its earnings estimates across 2027–2030, including lifting its 2030 EPS forecast to $6.84 from $5.73. It maintained a Buy rating and a $67 price target, signaling stronger longer-term profit expectations. Travere Therapeutics analyst information
• Positive Sentiment: Canaccord Genuity raised its price target to $72 from $70 and kept a Buy rating. Canaccord Genuity recommendations
• Neutral Sentiment: Guggenheim lowered its target to $78 from $89 but maintained a Buy rating, reflecting a more cautious valuation while remaining positive on the shares. Guggenheim recommendations
• Negative Sentiment: The main near-term headwind is Travere’s quarterly adjusted loss of $0.55 per share, substantially worse than the $0.06 loss analysts expected. Revenue beat estimates at $224.56 million and grew 36.2% year over year, but the earnings shortfall appears to have weighed on the stock. Travere shares gap down after earnings miss

Travere Therapeutics Company Profile

Travere Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases, with an emphasis on serious kidney conditions. The company’s work centers on addressing diseases with limited treatment options and improving outcomes for patients with progressive renal disorders.

Travere’s lead commercial product is FILSPARI (sparsentan), an oral treatment for adults with primary immunoglobulin A nephropathy (IgA nephropathy) who are at risk of disease progression.